Sign inCreate account

Report workspace tools

NCT01799798COMPLETEDanonymous

TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB

Sponsor

Source record

University of Cologne

Phase

Source record

Phase 2

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Osteogenesis Imperfecta

Indication / condition

AI-normalized

Osteogenesis Imperfecta

Intervention

Source record

Denosumab

Source & freshness

Source record

NCT ID

NCT01799798

Original source

ClinicalTrials.gov

Source last updated

Jan 27, 2015

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01799798

Title

TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB

Sponsor

University of Cologne

Status

COMPLETED

Phase

Phase 2

Condition raw

Osteogenesis Imperfecta

Condition normalized

Osteogenesis Imperfecta

Modality raw

Osteogenesis Imperfecta

Modality normalized

monoclonal antibody

Target raw

Osteogenesis Imperfecta

Target normalized

Osteogenesis Imperfecta

Interventions

Denosumab

Public preview

Source record

This pilot trial evaluated the efficacy of Denosumab, a RANKL antibody, in treating children aged 5-10 with Osteogenesis Imperfecta caused by COL1A1 or COL1A2 mutations. The study aimed to assess changes in bone mineral density (BMD) after 36 weeks of treatment.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01799798

Status

COMPLETED

Phase

Phase 2

Sponsor

University of Cologne

Executive brief

Investment-Ready Snapshot

This pilot trial evaluated the efficacy of Denosumab, a RANKL antibody, in treating children aged 5-10 with Osteogenesis Imperfecta caused by COL1A1 or COL1A2 mutations. The study aimed to assess changes in bone mineral density (BMD) after 36 weeks of treatment.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 27, 2015
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01799798

Indication

Osteogenesis Imperfecta

Modality

monoclonal antibody

Target

Osteogenesis Imperfecta

Intervention

Denosumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.